- Home
- BBNX vs CVAC Comparison
BBNX vs CVAC Comparison
Compare BBNX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBNX
- CVAC
- Stock Information
- Founded
- BBNX 2015
- CVAC 2000
- Country
- BBNX United States
- CVAC Germany
- Employees
- BBNX N/A
- CVAC N/A
- Industry
- BBNX Medical/Dental Instruments
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- BBNX Health Care
- CVAC Health Care
- Exchange
- BBNX Nasdaq
- CVAC Nasdaq
- Market Cap
- BBNX 841.5M
- CVAC 764.4M
- IPO Year
- BBNX 2025
- CVAC 2020
- Fundamental
- Price
- BBNX $17.89
- CVAC $5.44
- Analyst Decision
- BBNX Strong Buy
- CVAC Buy
- Analyst Count
- BBNX 10
- CVAC 3
- Target Price
- BBNX $25.20
- CVAC $9.00
- AVG Volume (30 Days)
- BBNX 504.1K
- CVAC 2.1M
- Earning Date
- BBNX 08-06-2025
- CVAC 08-14-2025
- Dividend Yield
- BBNX N/A
- CVAC N/A
- EPS Growth
- BBNX N/A
- CVAC N/A
- EPS
- BBNX N/A
- CVAC 0.87
- Revenue
- BBNX $69,830,000.00
- CVAC $566,039,775.00
- Revenue This Year
- BBNX $32.79
- CVAC N/A
- Revenue Next Year
- BBNX $36.59
- CVAC $24.04
- P/E Ratio
- BBNX N/A
- CVAC $6.34
- Revenue Growth
- BBNX 38911.17
- CVAC 787.60
- 52 Week Low
- BBNX $8.89
- CVAC $2.37
- 52 Week High
- BBNX $24.50
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- BBNX N/A
- CVAC 68.03
- Support Level
- BBNX N/A
- CVAC $4.07
- Resistance Level
- BBNX N/A
- CVAC $5.58
- Average True Range (ATR)
- BBNX 0.00
- CVAC 0.20
- MACD
- BBNX 0.00
- CVAC 0.07
- Stochastic Oscillator
- BBNX 0.00
- CVAC 83.08
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.